In conclusion, despite the fact that approaches seeking to enhance SCN1A gene expression/restore Nav1.1 function are already in clinical trials,1 Shao and colleagues have uniquely demonstrated the therapeutic efficacy of TAU-lowering therapeutics in neurodevelopmental disorders characterized by hyperexcitability. The gene discussed is SCN1A; the disease is neurodevelopmental disorder.